Ashish "The pandemic is still with us" Jha+ Your Authors @ashishkjha Physician, researcher, and advocate for the notion that an ounce of data is worth a thousand pounds of opinion. Director @harvardgh. Soon, Dean @Brown_SPH Jul. 20, 2020 1 min read + Your Authors

New @TheLancet study on Oxford Adenovirus vaccine out and is indeed good news

First, its an early phase trial -- assessing both safety and efficacy

Randomized -- about 500 folks in each arm

Its good news -- but we have to not over-state things


The vaccine uses a chimp adenovirus vector with the SARS-CoV2 spike protein (which SARS-CoV2 uses to enter into human cells)

First, safety data:

Most folks with vaccine (67%) had pain at injection site, fatigue (70%) headaches (68%). All short-lived, improved with tylenol


safety (contd):

No severe reactions in the active vaccine group.

Efficacy -- did vaccine elicit an immune response?

First, a primer:

There are two main arms of immune system: humoral (antibodies) and cellular (T-cells)

Immune system more complicated but lets be simple


Efficacy (immune response) continued:

1. Everyone (by the second dose) got neutralizing antibodies -- this is good news

2. Most folks formed a cellular response against the spike protein.

Immune response looked durable at least out to about 6 weeks



Vaccine appears safe in the short run, elicits a robust immune response.


So what do we NOT know (yet)??

First, whether vaccine is safe in longer run

Second, whether it actually prevents infections or at least severe infections (that's the point, right?)


So on to phase 3

Large trial with a much longer follow up for safety

And need to know if vaccines prevents (severe) infections

Need to test in kids, older folks

I'm very optimistic about vaccines in early 2021.

Until then, we have to protect as many lives as possible.


You can follow @ashishkjha.


Tip: mention @threader_app on a Twitter thread with the keyword “compile” to get a link to it.

Enjoy Threader? Sign up.

Since you’re here...

... we’re asking visitors like you to make a contribution to support this independent project. In these uncertain times, access to information is vital. Threader gets 1,000,000+ visits a month and our iOS Twitter client was featured as an App of the Day by Apple. Your financial support will help two developers to keep working on this app. Everyone’s contribution, big or small, is so valuable. Support Threader by becoming premium or by donating on PayPal. Thank you.

Follow Threader